Clinical trials: Blood-Borne Infections
HIV Infection
An Adaptive Platform Trial for Evaluation of Novel Treatment Regimens in Children and Adolescents With HIV in Africa
The goal of the CHAPAS-5 clinical trial is to find out how well different HIV treatments work in children and young people (from 4 weeks up to under 15 years old) living with HIV, including those starting treatment for the first…
- Trial name
- CHAPAS-5 (NCT07792096)
- Testing
- Dolutegravir (DTG), Abacavir (ABC), Lamivudine (3TC)
- Volunteers
- 800 people
- Sponsor
- University College, London
HIV Infections
A Randomized, Double-Blind Phase II/III Trial of Monotherapy vs. Combination Therapy With Nucleoside Analogs in HIV-Infected Persons With CD4 Cells of 200-500/mm3
To determine the efficacy and safety of zidovudine ( AZT ) versus didanosine ( ddI ), AZT plus ddI, and AZT plus zalcitabine ( ddC ) in preventing disease progression in HIV-infected patients with CD4 counts of 200-500 cells/mm3.
- Trial name
- NCT00000625
- Testing
- Zidovudine, Zalcitabine, Didanosine
- Where
- 58 sites in United States, Puerto Rico and 1 more
- Volunteers
- 2,100 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
ART Drug Dosage Adjustment in HIV-infected Population
The purpose of this study is to determine efficacy of the combination of low dose of Tenofovir, Efavirenz and Lamivudine in treating HIV-infection.
- Trial name
- NCT02632474
- Testing
- Tenofovir(TDF)+Lamivudine(3TC)+Efavirenz(EFV)
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Shanghai Public Health Clinical Center
Liver Fibrosis, Chronic Hepatitis B
A Clinical Evaluation on Traditional Chinese Medicine Diagnosis and Treatment Program Blocking and Reversing Hepatitis B-related Liver Fibrosis - a Randomized, Controlled, Double-blind, Multi-center Clinical Trial
This research puts liver biopsy as the enrollment screening criteria and the primary efficacy assessment indicators. Patients at different developmental stages of hepatitis B related liver fibrosis are respectively diagnosed and…
- Trial name
- NCT01965418
- Testing
- Fufang Biejia Ruangan Tablet
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Beijing 302 Hospital
HIV Infection
Combination Drug Treatment of Pediatric HIV Infection
This study will test the safety and effectiveness of hydroxyurea, an anti-cancer drug, given together with the anti-HIV drugs didanosine, stavudine and efavirenz for treating children infected with human immunodeficiency virus…
- Trial name
- NCT00001818
- Testing
- Hydroxyurea
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Hepatitis B, Chronic
Entecavir Resistance-Associated Mutations in Chronic HBV Patients in Turkey (STREAM Study)
Chronic hepatitis B is a long-term viral infection that affects millions of people worldwide. Patients usually require lifelong antiviral treatment to control the virus and prevent liver damage.
- Trial name
- NCT07459426
- Testing
- Viral genetic material from blood samples using advanced sequencing technology
- Where
- 10 sites in Turkey (Türkiye)
- Volunteers
- 700 people
- Sponsor
- Yaşar Bayındır, MD
Hiv
Kidney Transplantation From Donors With HIV: Impact on Rejection and Long-Term Outcomes (Expanding HOPE Kidney)
This research is being done to better understand rejection in transplant recipients with HIV who receive kidneys from donors with vs without HIV.
- Trial name
- NCT06263426
- Testing
- HIV D+/R+, HIV D-/R+
- Where
- 18 sites in United States
- Volunteers
- 200 people
- Sponsor
- Johns Hopkins University
Hepatitis B
Safety and Efficacy of a Hepatitis B Vaccine in Immunosuppressed Patients
This is a preliminary trial of a Hepatitis B vaccine (Heplisav-B) in medically immunosuppressed patients. The purpose of this study is to test the ability of Heplisav-B to produce high levels of antibody that neutralize the virus…
- Trial name
- NCT04199715
- Testing
- Heplisav-B
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Baylor Research Institute
HIV, HIV/AIDS
Peg-Interferon Alpha 2b Combined With Two Intravenous Broadly HIV-1 Neutralizing Antibodies 3BNC117 and 10-1074 (BEAT-2)
This study will evaluate the safety, tolerability and innate immune mechanisms activation following administration of the combination of Pegylated Interferon alpha 2b (peg-IFN-α2b) with two broadly neutralizing antibodies…
- Conditions
- HIV, HIV/AIDS, HIV-1 Infection
- Trial name
- BEAT-2 (NCT03588715)
- Testing
- Pegylated Interferon alpha 2b (peg-IFN-α2b), 3BNC117 + 10-1074
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Luis Montaner
HIV Infection
A Phase I, Randomized, Double-Blind, Placebo-Controlled Safety, Tolerability and Immunogenicity Study of Candidate HIV-1 Vaccines ChAdOx1.HTI and MVA.HTI With Recombinant HIV-1 Envelope Protein ConM SOSIP.v7 gp140 Vaccine, Adjuvanted With MPLA Liposomes in ART-Suppressed HIV-1 Positive Individuals
BCN03 is a Single-site, randomized, double-blind, placebo-controlled, phase I study to evaluate the safety, tolerability, immunogenicity, and efficacy of a vaccine regimen that includes a sequence of the T- and B-cell immunogens…
- Trial name
- NCT05208125
- Testing
- ChAdOx1.HTI at week 0, ConM SOSIP.v7 at weeks 4, 12 and 28, and MVA.HTI at week 22 (CSSMS)., Normal saline solution
- Where
- Spain
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- IrsiCaixa
Colitis, HIV Infections
A Randomized Comparative Pharmacokinetic Study of Oral Ganciclovir After Treatment With Intravenous Ganciclovir for Cytomegalovirus Gastrointestinal Disease in AIDS Patients
To determine the oral bioavailability of three dose levels of oral ganciclovir given with and without glutamic acid hydrochloride in patients with cytomegalovirus (CMV) GI disease, and to compare the bioavailability of these…
- Trial name
- NCT00000768
- Testing
- Glutamic acid hydrochloride, Ganciclovir
- Where
- 5 sites in United States
- Volunteers
- 24 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hepatitis C, Hemodialysis
Effect of HCV Infection on Insulin Resistance and Malnutrition-inflammation Complex Syndrome in Regular Hemodialysis Patients
The purpose of this study is to study whether hepatitis C virus (HCV)infected maintenance hemodialysis (MHD)patients have distinct metabolic, inflammatory and adipokine characteristics that can be linked to poor clinical outcome…
- Conditions
- Hepatitis C, Hemodialysis, Quality of Life, Mortality
- Trial name
- NCT00527774
- Where
- Taiwan
- Volunteers
- 200 people
- Sponsor
- St. Martin De Porress Hospital
HIV Infections, HIV Prevention
Community-based Outreach and Navigation for Nurse-led Engagement in HIV Care and Treatment
Many people who are experiencing homelessness are at high risk for HIV, but they often have trouble getting HIV prevention or treatment.
- Conditions
- HIV Infections, HIV Prevention, Homeless Persons, Homelessness
- Trial name
- CONNECT (NCT07870603)
- Testing
- CONNECT (status-neutral, nurse-led on-site HIV service delivery), Standard of Care (referral-based outreach)
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- Donaldson Conserve
Hepatitis B, Hepatitis A
Long-term Immune Persistence of GSK Biologicals' Combined Hepatitis A & B Vaccine Injected According to a 0,1,6 Mth Schedule in Healthy Adults
The aim of this study is to evaluate the long-term persistence of hepatitis A and B antibodies at Years 11, 12, 13, 14 and 15 after subjects received their first dose of a 3 dose primary vaccination schedule of combined hepatitis…
- Trial name
- NCT00289770
- Testing
- Twinrix™
- Where
- Belgium
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
HIV Infections, HSV-2 Infection
Immunogenetic Modulators of Mucosal Protection From HIV-1
This is a single site, prospective, observational study that seeks to assess changes in mucosal immunity that occur as a result of HIV-1 exposure, HSV-2 infection, and/or pre-exposure prophylaxis (PrEP) usage to prevent HIV-1…
- Trial name
- Kinga (NCT03701802)
- Where
- Kenya
- Volunteers
- 812 people, healthy volunteers welcome
- Sponsor
- University of Washington
HIV Infections
RAL-eve Study: Raltegravir Substitution Study
The purpose of this study is to: Provide raltegravir to subjects with HIV and an undetectable viral load who are experiencing injection site reactions (ISR) to Enfuvirtide, Monitor the safety and efficacy of raltegravir, and…
- Trial name
- NCT00523237
- Testing
- Raltegravir
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Stanford University
Hepatitis C Virus
A Study in Healthy Participants Investigating the Effect of TMC435 on the Pharmacokinetics of Immunosuppressants Cyclosporine and Tacrolimus
The purpose of this study is to investigate the effect of steady-state concentrations of TMC435 (administered once a day) on the single-dose pharmacokinetics of the immunosuppressants cyclosporine and tacrolimus in healthy…
- Trial name
- NCT01479881
- Testing
- tacrolimus, TMC435, cyclosporine
- Where
- Belgium
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Tibotec Pharmaceuticals, Ireland
HIV/AIDS
PrEPared and Strong: Clinic-Based PrEP for Black MSM
Black men who have sex with men (MSM) have among the highest rates of new HIV infections of any group in the United States. Developing effective HIV prevention interventions that work with this group is a critical element of the…
- Trial name
- P&S (NCT02167386)
- Testing
- Enhanced PrEP Adherence, Standard PrEP Adherence
- Where
- 2 sites in United States
- Volunteers
- 204 people, healthy volunteers welcome
- Sponsor
- Columbia University
HIV Seropositivity
A Multilevel, Multiphase Optimization Strategy for PrEP (MOST:PrEP)
What is known: There are 1.2 million people in the US who meet the indications for PrEP; yet, disparities exist in uptake. For example, only 9% of Black and 16% of Latino individuals, compared to 65% of White individuals, have…
- Trial name
- MOST:PrEP (NCT06334341)
- Testing
- Computer-based simulation training for providers, Best Practice Alert, HIV Risk Assessment
- Where
- United States
- Volunteers
- 1,380 people, healthy volunteers welcome
- Sponsor
- Henry Ford Health System
HIV Infections
A Randomized Phase II Study of Two Doses of Interferon Alfa-2a (IFN Alfa-2a) in Combination With Zidovudine (AZT) and Dideoxycytidine (ddC) Versus AZT and ddC Only in Patients With HIV Infection and Less Than 400 CD4 Cells/mm3
To determine the safety and efficacy of two doses of interferon alfa-2a ( IFN alfa-2a ) in combination with zidovudine ( AZT )/zalcitabine ( ddC ) versus AZT/ddC only in patients with HIV infection and CD4 count < 400 cells/mm3.
- Trial name
- NCT00000754
- Testing
- Interferon alfa-2a, Zidovudine, Zalcitabine
- Where
- 4 sites in United States
- Volunteers
- 60 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.